Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Endocrine 1Breast 1

Conditions

Neuroendocrine Tumors 69Carcinoma, Neuroendocrine 26Pheochromocytoma 23Thyroid Cancer, Papillary 21Pituitary Neoplasms 21Thyroid Neoplasms 20Adrenocortical Carcinoma 18Paraganglioma 15Multiple Endocrine Neoplasia Type 1 12Sarcoma 11Neuroblastoma 11Small Cell Lung Carcinoma 10Neoplasms 10Melanoma 9Lung Neoplasms 9Carcinoid Tumor 9Adrenal Gland Neoplasms 9Adenoma, Islet Cell 9Pancreatic Neoplasms 8Gastro-enteropancreatic neuroendocrine tumor 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Medullary 8Adenocarcinoma, Follicular 8Thyroid Carcinoma, Anaplastic 7Ovarian Neoplasms 7Neoplasm Metastasis 7Cushing Syndrome 7Cholangiocarcinoma 7Central Nervous System Neoplasms 7Breast Neoplasms 7

Interventions

fludarabine 1aldesleukin 1Nivolumab 1Ipilimumab 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Giant Cell Tumor of Bone × Endocrine × 90 days × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡